Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Vanguard High Dividend Yield ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Vanguard High Dividend Yield ETF trades at $159.3 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 20.7× Travere Therapeutics Inc. Common Stock's market cap, and Vanguard High Dividend Yield ETF is more actively traded (834,323 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Vanguard High Dividend Yield ETF for 140 Days on average.
| TVTX | VYM | |
|---|---|---|
Market Cap | $4.88B | $100.80B |
Volume | 1,668,577 | 834,323 |
Sector | Health | — |
52-Week High | $67.52 | $167.03 |
52-Week Low | $26.79 | $138.43 |
Typical Hold Time | 0 Days | 140 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
VYM trades at $159.11, down slightly by 0.08% today, with a bullish technical signal from moving averages despite neutral oscillators. The ETF maintains strong sector diversification and a 2.42% dividend yield, though recent news highlights competition from alternatives like SCHD and IDV. Support levels are clustered around $157-158, with resistance at $160-161.
Outlook remains mixed; VYM offers steady income but faces pressure from higher-yielding or better-performing peers. Key risks include dividend cuts in holdings like Intel and Walgreens, while institutional sentiment leans cautious due to moderate growth prospects versus competing ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
